InsiderSource
ELVN

Enliven Therapeutics, Inc.

SEC CIK 1672619
$44.86 +59.8% · 90 days
90-day buys
$0
0 open-market
90-day sells
$2.19M
11 open-market
Net insider flow
−$2.19M
Net selling
Filings shown
111
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at ELVN have sold a net $2.19M of stock (0 open-market buys vs 11 sells).

Largest recent trade: Lyssikatos Joseph P sold $1.46M of ELVN, trimming their stake 6%.

Most active filer: Lyssikatos Joseph P, with 42 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for ELVN, newest first
View on SEC EDGAR ↗
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 22, 2026 ΔOwn −1.9%

Lyssikatos Joseph P sold $390.3K of ELVN, trimming their stake 2%.

−$390.3K
14,509 sh @ $27
ELVN
Enliven Therapeutics, Inc.
Sell Patel Anish · CHIEF OPERATING OFFICER · Open-market sale · filed Jan 13, 2026 ΔOwn −18%

Patel Anish sold $1.34M of ELVN, trimming their stake 18%.

−$1.34M
48,057 sh @ $28
ELVN
Enliven Therapeutics, Inc.
Sell Patel Anish · CHIEF OPERATING OFFICER · Open-market sale · filed Jan 13, 2026 ΔOwn −0.1%

Patel Anish sold $6.9K of ELVN.

−$6.9K
243 sh @ $29
Advertisement
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 12, 2026 ΔOwn −4.8%

Lyssikatos Joseph P sold $1.03M of ELVN, trimming their stake 5%.

−$1.03M
41,198 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 12, 2026 ΔOwn −6.1%

Lyssikatos Joseph P sold $1.46M of ELVN, trimming their stake 6%.

−$1.46M
50,000 sh @ $29
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 12, 2026 ΔOwn −0.8%

Lyssikatos Joseph P sold $151K of ELVN, trimming their stake 1%.

−$151K
7,500 sh @ $20
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 12, 2026 ΔOwn −3.8%

Lyssikatos Joseph P sold $842.5K of ELVN, trimming their stake 4%.

−$842.5K
33,802 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Dec 23, 2025 ΔOwn −0.6%

Lyssikatos Joseph P sold $84.2K of ELVN, trimming their stake 1%.

−$84.2K
5,000 sh @ $17
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Nov 21, 2025 ΔOwn −1.3%

Lyssikatos Joseph P sold $267.8K of ELVN, trimming their stake 1%.

−$267.8K
12,008 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Oct 22, 2025 ΔOwn −1.3%

Lyssikatos Joseph P sold $276K of ELVN, trimming their stake 1%.

−$276K
12,500 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Oct 1, 2025 ΔOwn −12%

Hohl Benjamin sold $66.3K of ELVN, trimming their stake 12%.

−$66.3K
3,250 sh @ $20
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Sep 23, 2025 ΔOwn −0.5%

Lyssikatos Joseph P sold $93.1K of ELVN, trimming their stake 1%.

−$93.1K
4,870 sh @ $19
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Aug 29, 2025 ΔOwn −12%

Hohl Benjamin sold $67K of ELVN, trimming their stake 12%.

−$67K
3,250 sh @ $21
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Aug 21, 2025 ΔOwn −0.8%

Lyssikatos Joseph P sold $150.1K of ELVN, trimming their stake 1%.

−$150.1K
7,500 sh @ $20
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Aug 21, 2025 ΔOwn −0.5%

Lyssikatos Joseph P sold $98.1K of ELVN, trimming their stake 1%.

−$98.1K
5,000 sh @ $20
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 30, 2025 ΔOwn −12%

Hohl Benjamin sold $65.1K of ELVN, trimming their stake 12%.

−$65.1K
3,185 sh @ $20
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jul 23, 2025 ΔOwn −1.2%

Lyssikatos Joseph P sold $265.5K of ELVN, trimming their stake 1%.

−$265.5K
11,924 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 14, 2025 ΔOwn −4.2%

Hohl Benjamin sold $22.7K of ELVN, trimming their stake 4%.

−$22.7K
1,000 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 1, 2025 ΔOwn −12%

Hohl Benjamin sold $63.7K of ELVN, trimming their stake 12%.

−$63.7K
3,052 sh @ $21
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 1, 2025 ΔOwn −0.9%

Hohl Benjamin sold $4.3K of ELVN, trimming their stake 1%.

−$4.3K
198 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jun 24, 2025 ΔOwn −1.3%

Lyssikatos Joseph P sold $267.5K of ELVN, trimming their stake 1%.

−$267.5K
12,500 sh @ $21
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jun 17, 2025 ΔOwn −12%

Hohl Benjamin sold $67.7K of ELVN, trimming their stake 12%.

−$67.7K
3,000 sh @ $23
Advertisement

About ELVN insider activity

This page tracks every recent Form 4 filed for Enliven Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is ELVN insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Enliven Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.